Close Menu

NEW YORK – UK-based gene synthesis firm Evonetix announced Monday it has closed a £23million ($29.4 million) Series B financing round.

New investor Foresite Capital led the round, joined by existing investors Draper Esprit, DCVC, the Morningside Group, Providence Investment Company, Cambridge Consultants, Rising Tide Fund, and Civilization Ventures. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.